Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age40+
SponsorMazandaran University of Medical Sciences
About this trial
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
Eligibility criteria
Qualifiers
signing inform consent,
recent ischemic stroke within 24 h,
diagnosed by brain CT or MRI mild stroke with NIHSS =<8 and no evidence of large infarct in brain imaging
high risk TIA with ABCD >4,
Disqualifiers
history of hypersensitivity to consumptive drug
any indication for anticoagulant therapy
acute phase treatment with intravenous thrombolysis or thrombectomy
any contraindication for consumptive drug
Trial design
Treatments tested in this trial
- Ticagrelor 60 + Aspirin
- Ticagrelor 90 + aspirin
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov